SynenTec To Take Over Roche Cellavista System
03-08-2012: Roche and SynenTec announced that Roche will transfer its Cellavista business to SynenTec, the German company which is the original inventor of the Cellavista System. This agreement was made as a result of the Roche Applied Science decision to focus its business, and guarantees future optimal support and development of the technology for its customers.
The Cellavista Imaging System for noninvasively measuring cell expansion uses brightfield and fluorescence detection with multiwell plates, chamber slides or RoboFlasks, for a broad range of cellular applications in cell line development, cellular research and drug discovery.
“It is very important that we ensure uninterrupted support for our customers. We have found the ideal match in SynenTec”, said Dan Zabrowski, Head of Roche Applied Science.
“This acquisition adds significant value for Cellavista customers by enabling them to directly discuss their requirements and needs with the developer of the system,” says Matthias Pirsch, CEO of SynenTec.
Over the last years, SynenTec collaborated with Roche in cell imaging, and was closely involved in the development, service and support of Cellavista Systems. With the business transfer SynenTec will take on worldwide distribution of Cellavista Systems, as well as providing application support and service. Roche will remain the primary contact partner for all support needs for Cellavista Systems delivered by Roche or Innovatis over a transition phase until SynenTec assumes full responsibility on June 01, 2013.
- cell analysis
- 1Schleicher & Schuell has been purchased by Whatman plc
- 2Identifying microbial species
- 3Merger of CyBio AG into Analytik Jena AG Completed
- 4Sophisticated radiation detector designed for broad public use
- 5SP Industries Acquires Bel-Art Products
- 6The quantum dance of oxygen
- 7LIMS/LIS Market and POCT Supplement
- 8KNAUER among Top 100 innovators
- 9Danaher Announces Definitive Agreement to Acquire Leica Microsystems
- 10Siemens Healthcare agrees to sell microbiology business to Beckman Coulter